Affimed Therapeutics, a German therapeutic TandAb antibody company, has reorganised its management team under the leadership of Adi Hoess and Rolf Guenther.
Hoess, previously chief commercial officer, is now chief executive, while Guenther, previously chief executive, is now chief operating officer with a focus on advancing the pipeline through clinical trials.
"With a platform technology allowing development of multiple product candidates it is now time to adapt the organisation to the new needs,’ said Thomas Hecht, chairman of Affimed.
‘I am confident that under the leadership of Adi with his extensive business background in commercial operations and M&A strategies and with Rolf focusing on the clinical development of our core assets and overseeing the operations we have set up the company not only to build on its assets but also to prepare for its future.’
Affimed reorganises management team
Adi Hoess becomes chief executive
You may also like
Research & Development
![Rethinking the route to first-in-human studies]()
Rethinking the route to first-in-human studies
For sponsors, development activities and fragmented clinical supply can slow the path from candidate selection to first-in-human (FIH) dosing. A more integrated approach can reduce avoidable complexity while preserving the flexibility needed for early clinical programmes
Research & Development
![Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine]()
Stablepharma doses first participant in Phase IIb trial of fridge-free tetanus-diphtheria vaccine
The 160-person non-inferiority study is the final development step for the StablevaX-reformulated vaccine SPVX02, before commercialisation of a cold-chain-independent alternative to Tetadif
Manufacturing
![Making blister package integrity testing decisions that QA can use]()
Making blister package integrity testing decisions that QA can use
A blister package integrity testing strategy should give QA evidence that is relevant, repeatable, and practical to review. That means understanding the pack format, the likely leak risk, the sampling approach, and the records needed for routine decisions
